Pharmaceutical companies including AbbVie, Johnson & Johnson, Bristol Myers Squibb, Takeda, and Astex have formed a consortium to share proprietary structural data, boosting AI-powered drug discovery's accuracy and scope. Concurrently, new AI-driven models demonstrate strong performance in prostate cancer detection and Gleason score prediction from MRI, and advancements in deep learning streamline lung cancer lymph node delineation for radiotherapy. Additionally, novel spatial proteomics software integrates multiomic data for cancer research, supporting more precise tumor microenvironment analysis. These developments underscore AI’s growing role in diagnostics, drug design, and personalized oncology treatment.